GSK to acquire U.S.-based BELLUS Health for $14.75 per share
April 18, 2023 at 02:33 AM EDT
GSK said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Calendar | Directory | Real Estate | Blog | More
|